Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study - PubMed
5 hours ago
- #hepatocellular carcinoma
- #portal vein invasion
- #immunotherapy
- Durvalumab combined with hepatic arterial infusion chemotherapy (HAIC) using FOLFOX, followed by maintenance durvalumab, shows promising efficacy in a phase 2 study for hepatocellular carcinoma (HCC) patients with major portal vein invasion (Vp3/4 PVTT).
- The study achieved its primary endpoint with a 1-year overall survival rate of 63.3% and a median overall survival of 13.9 months, indicating improved outcomes for a high-risk patient group.
- Biomarker analyses revealed that responders exhibited increased immune infiltration and stronger immune-tumor interactions, while nonresponders showed signatures of chemotherapy resistance and immune escape, including a specific malignant subcluster (MECOM+).
- Treatment was associated with expanded T-cell subsets and enhanced cytotoxic gene expression in peripheral blood, particularly in responders, alongside a reduction in nonclassical monocytes and anti-inflammatory phenotypes.
- The combination therapy demonstrated generally tolerable toxicity, offering a potential first-line treatment option and providing candidate biomarkers for predicting response in HCC with major portal invasion.